Betaglycan, also known as TGF-β type III receptor, is a membrane-anchored proteoglycan, which has two glycosaminoglycan (GAG) attachment sites (López-Casillas et al. J. Cell Biol. 1994, 124, 557-568). Chondroitin sulfate (CS) or heparan sulfate (HS) can attach to the first site, Ser 535 , whereas only CS attaches to the second, Ser 546 . Although the mechanism behind the assembly of CS and HS is not fully understood, it has been reported that the assembly of HS requires not only a appreciable acceptor activity for α4GlcNAcT-I.
cluster of acidic residues but also hydrophobic residues located near the Ser-Gly attachment sites (Esko, J.D. Zhang, L. Curr. Opin. Struct. Biol. 1996, 6, 663-670) .
To further understand the effects of amino acids close to the Ser residues of the GAG-attachment sites on the glycosyltransferases, two tetraosyl peptides derived from the CS attachment sites of betaglycan, GlcA-Gal-Gal-Xyl-SerGlyAspAsnGly
(1) and GlcA-Gal-Gal-Xyl-SerGlyAspAsnGlyPheProGly (2), were synthesized, and used as donor substrates for β1,4-N-acetylgalactosaminyltransferase-I (β4GalNAcT-I) and α1,4-N-acetylglucosaminyltransferase-I (α4GlcNAcT-I). Both the chemically synthesized linkage region tetrasaccharides were far better acceptors for β4GalNAcT-I than for α4GlcNAcT-I in vitro, although they also showed
Introduction
Glycosaminoglycans (GAGs) are linear polysaccharide side chains of proteoglycans (PGs), and are composed of two parts, a linkage tetrasaccharide, glucuronic acid-galactose-galactose-xylose (GlcAβ1-3Galβ1-3Galβ1-4Xylβ1-O-), which is covalently linked to the respective core-protein through the hydroxyl group of the serine residue(s), and a repeating disaccharide region formed by hexosamine and hexuronic acid. GAGs are classified into a chondroitin sulfate (CS) type and a heparan sulfate (HS) type based on the hexosamine residues of the repeating disaccharides ( Fig. 1 ). In the endoplasmic reticulum and Golgi apparatus, the family, respectively. [2] [3] [4] Thus, the first transfer of the hexosamine residue, α-GlcNAc or β-GalNAc, which is the fifth saccharide from the reducing terminal, is crucial in determining the type of GAG, HS or CS.
( Figure 1) Betaglycan, also known as transforming growth factor (TGF)-β type III receptor, contains two Ser residues bearing a CS and/or HS chain in most mammalian cells. 5 Ser 535 can have either CS or HS, whereas Ser 546 only bears CS. [5] [6] [7] Zhang and Esko demonstrated that the synthesis of a HS chain on betaglycan requires a cluster of acidic amino acids and tryptophan residues located near the Ser-Gly of the GAG-attachment site using betaglycan chimeras, created by fusing short peptides to Protein A and/or polyhistidine tags and expression in Chinese hamster ovary cells. 7 However, the molecular mechanism behind the assembly of HS and CS at GAG attachment sites is still unclear. The use of synthetically available substrates is one of the best approaches to elucidating the regulation of the enzymatic elongation of glycan. To further understand the differential assembly of HS and CS chains, this paper reports the facile synthesis of partial structures of betaglycan having the GAG-protein linkage tetrasaccharide attached to Ser 546 with peptides of different lengths, GlcA-Gal-Gal-Xyl-SerGlyAspAsnGly (1) and
GlcA-Gal-Gal-Xyl-SerGlyAspAsnGlyPheProGly (2). In addition, enzymatic transfers of β-GalNAc and α-GlcNAc to the non-reducing terminus of not only these linkage region tetrasaccharide-peptides but also GlcA-Gal-Gal-Xyl-Ser 535 GlyTrpProAspGly (3) 8 , which was synthesized previously, were performed to produce acceptor substrates for β4GalNAcT-I and α4GlcNAcT-I using human CS N-acetylgalactosaminyltransferase 2 (CSGalNAcT2) 9 and exostosin-like 3 (EXTL3) 4,10 as enzyme sources, respectively.
Results and Discussion
To obtain the linkage tetrasaccharide in fewer steps than previously reported, 8
GlcA-Gal + Gal-Xyl glycosylation was adopted. As depicted in Scheme 1, the GlcA-Gal moiety was prepared by coupling glucuronosyl trichloroacetimidate (4) 11 with the galactosyl acceptor (5) 12 in the presence of TMSOTf in CH 2 Cl 2 to give the β-linked disaccharide (6) in 24% yield together with the recovery of 5 in 60% yield.
The coupling yield to obtain GlcA-Gal depends on the substrates. 13, 14 Some efforts have been made to increase the yield by protecting the acceptors with benzyl ether 15 or silylene acetal 14 . Although these modifications are effective, here, importance was attached to shortening steps for immediate synthesis. The disaccharide (6) was converted to the corresponding hemiacetal by the removal of the 4-methoxyphenyl group with CAN, and subsequent trichloroacetimidation with CCl 3 CN and DBU afforded 7 in 69 and 87% yields, respectively. Compound 7 was coupled with the disaccharide acceptor (8) 8 in the presence of TMSOTf to give the desired tetrasaccharide (9β) in 47% yield. Even with the acetyl group at the 2-O position of the glycosyl donor, the α-isomer (9α) was obtained in 24% yield. Starting from methyl tetra-O-acetyl-β-D-glucopyranosyl uronate, 4-methoxyphenyl 2,4,6-tri-O-acetyl-3-O-allyl-β-D-galactopyranoside, and 8, tetrasaccharide (9β) was obtained in 7 steps, while 11 steps were needed previously. 8 The tetrasaccharide (9β) was converted to the corresponding imidate (10) in 88% yield (2 steps) in the same manner as above.
The serylglycine allyl ester protected with Fmoc at the N-terminal (11) 16 was glycosylated with 10 in a TMSOTf-mediated manner to give 12 in 92% yield. The allyl group of 12 was removed with Pd(PPh 3 ) 4 and N-methylmorpholine to obtain the corresponding carboxylic acids (13) in 93% yield. Another target, 2, was synthesized on the Sieber amide resin (Scheme 3). The elongation was performed manually by the Fmoc procedure employing HOBt, HBTU, and DIPEA in NMP. Fmoc was removed with piperidine in NMP. The N-terminal of the hexapeptide on the resin was coupled with 13 in the same manner as for the peptide elongation. Then the glycosyl peptide on resin was treated with a TFA cocktail to give the corresponding tetraosyl octapeptide without the tert-butyl and trityl groups. Careful saponification as described for the synthesis of 1 furnished the desired tetraosyl octapeptide 2, which was purified by gel-permeation (LH-20) and HPLC (C8). Tetraosyl penta-and octapeptides (1 and 2) were completely assigned by 1 H NMR spectroscopy and by MALDI-TOFMS.
(Scheme 3)
To study the mechanism behind the assembly of CS and HS, the glycosyltransferase activities were assayed using the tetraosyl peptides (1, 2, and 3) as the sugar acceptors and either UDP-GalNAc or UDP-GlcNAc as a sugar donor. The enzymes used were soluble forms of CSGalNAcT2 9 and EXTL3 4 secreted into the culture medium by COS-7 cells transfected with the respective expression vectors.
CSGalNAcT2 and EXTL3 transfer β-GalNAc and α-GlcNAc at the GlcA terminal to elongate the linkage tetrasaccharide toward CS and HS via the glycosyltransferase activities of β4GalNAcT-I and α4GlcNAcT-I, respectively. It is worth noting that β-GalNAc and α-GlcNAc were transferred to both the tetraosyl oligopeptides, GlcA-Gal-Gal-Xyl-S (546) GDNG and GlcA-Gal-Gal-Xyl-S (546) GDNGFPG (1 and 2), though with remarkably higher activity for β-GalNAc than for α-GlcNAc (Table 1 and Fig. 2 ). These results were compatible with the fact that the naturally occurring betaglycan has only CS at Ser 546 . The next issue addressed was whether the tetraosyl oligopeptide, GlcA-Gal-Gal-Xyl-S (535) GWPDG (3), in which the Ser residue corresponds to a potential GAG attachment site for both HS and CS 5, 7 , serves as an acceptor substrate for α4GlcNAcT-I and β4GalNAcT-I. Similar β4GalNAc transferase activity of CSGalNAcT2 was observed using 1, 2, or 3 as an acceptor, suggesting β4GalNAcT-I to be little influenced by the amino acid sequences around the GAG attachment site, consistent with previous reports. 7, 9, 17 It has been proposed that α4GlcNAcT-I requires a hydrophobic aglycon moiety of the core protein in the acceptor substrate, which enhanced HS biosynthesis and α4GlcNAcT-I activity in a cell system and in vitro, respectively. 6, 7, 17 Unexpectedly, the amount of α4GlcNAc transferred by EXTL3 to GlcA-Gal-Gal-Xyl-SGWPDG (3) was comparable to that transferred to GlcA-Gal-Gal-Xyl-SGDNG (1) and GlcA-Gal-Gal-Xyl-SGDNGFPG
(2) ( Table 1) . Therefore, α4GlcNAcT-I of EXTL3 may not always require tryptophan and/or a hydrophobic residue near the GAG attachment site although they appear to be enhancer elements. 6 Alternatively or in addition, other EXT family members like EXT1 and EXT2 may be involved in the initiation/elongation of a HS chain at this particular site. In fact, the EXT1/EXT2 complex, HS-polymerase, could synthesize heparan polymers in vitro on GlcA-Gal-Gal-Xyl-SGWPDG (3) but not on GlcA-Gal-Gal-Xyl-(G)SGE, which corresponds to the CS attachment site of α-thrombomodulin. 3 (Table 1 )
Conclusions
Partial sequences of betaglycan having a linkage tetrasaccharide at Ser 546 , the site of attachment of CS but not HS in vivo, were synthesized with peptides of different lengths. The newly synthesized PG primers 1 and 2 proved to be superior acceptors for β-GalNAc than for α-GlcNAc transfers. However, they also showed appreciable activity as an acceptor for α4GlcNAc. 
Experimental

General methods
4-Methoxyphenyl O-[methyl 2,3,4-tri-O-acetyl-β-D-glucopyranosyl uronate]-(1→3)-O-2,4,6-tri-O-acetyl-β-D-galactopyranoside (6)
To a solution of methyl 2,3,4-tri-O-acetyl-D-glucopyranuronosyl trichloroacetimidate (4 11 , 9.82 g, 20.5 mmol) and 4-Methoxyphenyl 2,4,6-tri-O-acetyl-β-D-galactopyranoside (5 16 , 3.30 g, 8.00 mmol) in CH 2 Cl 2 (220 mL) was added MS AW300 (25 g). This mixture was stirred for 50 min at room temperature, and cooled to -20 °C. To this solution was added TMSOTf (1.12 mL, 6.19 mmol) with stirring and the reaction temperature was gradually raised to -10 °C for 2 h. Then, an excess amount of satd NaHCO 3 was added. Insoluble materials were filtered on Celite. The organic phase was treated as described in general methods. The volatiles were removed under diminished pressure and the residue was subjected to gel-permeation (LH-20, 1:1 CHCl 3 :MeOH) and applied to a column of silica gel (5:1-4:1-3:1-2:1 toluene-EtOAc) to give 6 (1.40 g) in 24% yield as a syrup. Acceptor Hz, H-4 IV ), 5.19 (dd, 1H, J 2,3 = 8. 9 
4-Methoxyphenyl O-(methyl 2,3,4-tri-O-acetyl-β-D-glucopyranosyl uronate)-(1→3)-O-(2,4,6-tri-O-acetyl-β-D-galactopyranosyl)-(1→
3)-O-(2,4,6-tri-O-acetyl-β-D-galactopyranosyl)-(1→
4)-2,3-di-O-(4-methylbenzoyl)-D-xylopyranosyl trichloroacetimidate (10)
To a solution of 9β (1.28 g, 924 mmol) in CH 3 CN (178 mL) and H 2 O (30 mL) was added CAN (2.03 g, 3.70 mmol) at 0 °C with stirring. After 1.5 h, additional CAN (0.51 g, 0.93 mmol) was supplied and the reaction mixture was stirred for another 1 h, then diluted with CHCl 3 and brine, and extracted with CHCl 3 . The organic phase was washed with brine and the residue was eluted from a column of silica gel (2:3-3:7-1:10 toluene-EtOAc) to give the corresponding hemiacetal (1.04 g, 88%) as a syrup. The hemiacetal was diluted with CH 2 Cl 2 (19 mL). To the solution were added CCl 3 CN (816 µL) and DBU (48 µL) at 0 °C. The reaction mixture was stirred for 1.5 h and applied directly to a column of silica gel (1:2-1:4 toluene-EtOAc) to give 10 quantitatively as a syrup. The characteristic anomeric proton and NH signals of 10 were detected with 1 H NMR measurements. The imidate 10 was used for the next reaction without further purification.
N-(9-Fluorenylmethoxycarbonyl)-O-[(methyl
2,3,4-tri-O-acetyl-β-D-glucopyranosyl uronate)-(1→
3)-O-(2,4,6-tri-O-acetyl-β-D-galactopyranosyl)-(1→
4)-2,3-di-O-(4-methylbenzoyl)-β-D-xylopyranosyl]-L-serylglycine allyl ester (12)
To a solution of N-(9-fluorenylmethoxycarbonyl)-L-serylglycine allyl ester (11 16 , 486.0 mg, 1.14 mmol) and 10 (814.4 mg, 572 µmol) in CH 2 Cl 2 (83 mL) was added MS AW300 (2.3 g). This mixture was stirred for 30 min at room temperature, and then cooled to -20 °C. To this solution was added TMSOTf (72 µL, 397 µmol)
with stirring for 2 h. The reaction was quenched and treated as described for the N-(9-Fluorenylmethoxycarbonyl)-O-[(methyl   2,3,4 
-tri-O-acetyl-β-D-glucopyranosyl uronate)-(1→
3)-O-(2,4,6-tri-O-acetyl-β-D-galactopyranosyl)-(1→
4)-2,3-di-O-(4-methylbenzoyl)-β-D-xylopyranosyl]-L-serylglycine (13)
Tetrakis(triphenylphosphine)palladium (0) 
N-(Butoxycarbonyl)-L-asparaginylglycine methyl ester (14)
Boc-Asn-OH (2.70 g, 11.6 mmol) and H-Gly-O-Me•HCl (1.46 g, 11.6 mmol) were dissolved in CH 2 Cl 2 (150 mL). To this solution were added Et 3 N (1.60 mL, 11.5 mmol) and HOBt (3.15 g, 23.3 mmol) with stirring. The mixture was cooled to -20 °C, and then a solution of WSCD•HCl (2.45 g, 12.8 mmol) in CH 2 Cl 2 (21 mL) was added.
The reaction mixture was stirred overnight at room temperature. The volatiles were removed under diminished pressure, and the residue was applied to a column of silica gel (50:1-16:1 EtOAc-MeOH containing 1% AcOH) to give 14 (1.36 g) in 39% yield.
This compound was used for the next reaction without further purification. 1 
L-Asparaginylglycine methyl ester (15)
Trifluoroacetic acid (13 mL) was added to a solution of 14 (602 mg, 1.98 mmol) in CH 2 Cl 2 (13 mL) and the mixture was stirred for 1 h. The volatiles were removed under diminished pressure to give 15 quantitatively. All of this compound was used for the next reaction without further purification. 1 
4.10.
N-(9-Fluorenylmethoxycarbonyl)-O-(tert-butyl)-L-aspartyl-L-asparaginylglycine methyl ester (16)
FmocAsp(O-tBu)-OH (1.39 g, 3.39 mmol) and the dipeptide (15, 1.98 mmol) obtained above were dissolved in CH 2 Cl 2 (13 mL). To this solution were added Et 3 N (353 µL, 2.55 mmol) and HOBt (0.92 g, 6.8 mmol) with stirring. The mixture was cooled to -20 °C, and then a solution of WSCD•HCl (1.30 g, 6.78 mmol) in CH 2 Cl 2 (10 mL) was added. The reaction mixture was stirred overnight at room temperature, Calcd. for C 30 H 36 N 4 O 9 : C, 60.40; H, 6.08; N, 9.39. Found: C, 59.90; H, 6.31; N, 9.39. O-[β-D-Glucopyranuronosyl-(1→3)-O-β-D-galactopyranosyl-(1→ and CH 2 Cl 2 (2.2 mL) (3 x 1 min), and dried in vacuo. O-[β-D-Glucopyranuronosyl-(1→3)-O-β-D-galactopyranosyl-(1→ 
O-(tert-Butyl)-L-aspartyl-L-asparaginylglycine methyl ester (17)
3)-O-β-D-galactopyranosyl-(1→
4]-β-D-xylopyranosyl]-L-serylglycyl-L-aspartyl-L-asparaginylglycine (1)
4.15.
3)-O-β-D-galactopyranosyl-(1→
